Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?
- 1 September 2016
- journal article
- research article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 8 (9) , E1068-E1071
Abstract
Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?Keywords
This publication has 16 references indexed in Scilit:
- Mechanisms of Plaque Formation and RuptureCirculation Research, 2014
- Inflammation and its Resolution as Determinants of Acute Coronary SyndromesCirculation Research, 2014
- Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular DiseaseAmerican Journal of Cardiovascular Drugs, 2014
- New Therapeutic Targets in CardiologyCirculation, 2012
- The p38 mitogen-activated protein kinase pathway—A potential target for intervention in infarction, hypertrophy, and heart failureJournal of Molecular and Cellular Cardiology, 2011
- Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking TalePhysiological Reviews, 2010
- Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunctionNature Materials, 2008
- Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial InfarctionThe Journal of Pharmacology and Experimental Therapeutics, 2008
- p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the ratJACC, 2004
- p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulationCardiovascular Research, 2002